This Guidewire Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating for UroGen Pharma Ltd. (NASDAQ:URGN) from Buy to Neutral. UroGen Pharma shares closed at $4.17 on Wednesday. See how other analysts view this stock.
• DA Davidson analyst Peter Heckmann downgraded Guidewire Software, Inc. (NYSE:GWRE) from Buy to Neutral and announced a $226 price target. Guidewire Software shares closed at $210.84 on Wednesday. See how other analysts view this stock.
• Barclays analyst Lydia Rainforth downgraded the rating for Equinor ASA (NYSE:EQNR) from Overweight to Equal-Weight. Equinor shares closed at $23.62 on Wednesday. See how other analysts view this stock.
• Wedbush analyst Laura Chico downgraded Vigil Neuroscience, Inc. (NASDAQ:VIGL) from Outperform to Neutral and lowered the price target from $13 to $8. Vigil Neuroscience shares closed at $2.31 on Wednesday. See how other analysts view this stock.
• Citigroup analyst Patrick Donnelly downgraded Bruker Corporation (NASDAQ:BRKR) from Buy to Neutral and cut the price target from $50 to $40. Bruker shares closed at $36.45 on Wednesday. See how other analysts view this stock.

Considering buying GWRE stock? Here’s what analysts think:

Read This Next:

• Jim Cramer Recommends Not Buying Mosaic, Doesn’t Like This Industrial Stock

Photo via Shutterstock